For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.
Get full access to this article
View all access options for this article.
References
1.
KiriharaT., TaniguchiT., YamamuraK., et al.Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent. Invest. Opthalmol. Vis. Sci. 59:145–153, 2018.
2.
AiharaM., LuF., KawataH., et al.Pharmacokinetics, safety and IOP lowering profiles of omidenepag isopropyl, a selective EP2 agonist in healthy Japanese and Caucasian volunteers (phase 1 study). Invest. Ophthalmol. Vis. Sci. 58:2104, 2017.
3.
FuwaM., TorisC.B., FanS., et al.Effect of a novel selective EP2 receptor agonist, Omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys. J. Ocul. Pharmacol. Ther. 34:1–7, 2018.
4.
DugganS.Omidenepag isopropyl ophthalmic solution 0.002% first global approval. Drugs. 78:1925–1929.
5.
WoodwardD.F., LawrenceR.A., FairbairnC.E., et al.Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies. J. Lipid Med. 6:545–553, 1993.
6.
ColemanR.A., SmithW.L., and NarumiyaS.VIII. International Union of Pharmacology Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46:205–229, 1994.
7.
WoodwardD.F., JonesR.L., and NarumiyaS.International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev., 63:471–538, 2011.
8.
ReganJ.W., BaileyT.J., PepperlD.J., et al.Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol. 46:213–220, 1994.
9.
PierceK.L., GilD.W., WoodwardD.F., and ReganJ.W.Molecular cloning of human prostanoid receptors. Trends Pharmacol. Sci. 16:253–256, 1995.
10.
WangJ.W., WoodwardD.F., and MartosJ.L.Multitargeting of selected prostanoid receptors provides agents with enhanced anti-inflammatory activity in macrophages. FASEB J. 30:394–404, 2016.
11.
WoodwardD.F., BogardusA.M., and DonelloJ.Molecular characterization and ocular pharmacology of the prostanoid EP2 receptor. J. Ocul. Pharmacol. 11:447–454, 1995.
12.
WoodwardD.F., ReganJ.W., LakeS., and OcklindA.The molecular biology and ocular distribution of prostanoid receptors. Surv. Ophthalmol. 41:515–521, 1997.
13.
GardinerP.J.Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979. Br. J. Pharmacol. 87:45–56, 1986.
14.
SäfholmJ., DahlénS.E., DelinI., et al.PGE2 maintains the tone of the guinea pig trachea through a balance between activation of contractile EP1 receptors and relaxant EP2 receptors. Br. J. Pharmacol. 168:794–806, 2013.
15.
NorelX., WalchL., LabatC., et al.Prostanoid receptors involved in the relaxation of human bronchial preparations. Br. J. Pharmacol. 126:867–872, 1999.
16.
SeniorJ., MarshallK., SanghaR., and ClaytonJ.K.In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br. J. Pharmacol. 108:501–506, 1993.
17.
ArmstrongR.A.Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br. J. Pharmacol. 116:2903–2908, 1995.
18.
KayL.J., YeoW.W., and PeachellP.T.Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br. J. Pharmacol. 147:707–713, 2006.
19.
VassiliouE., JingH., and GaneaD.Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell Immunol. 223:120–132, 2003.
20.
WoodwardD.F., WangJ.W., NiM., et al.In vivo studies validating multi-targeting of prostanoid receptors for achieving superior anti-inflammatory effects. FASEB J. 31:368–375, 2017.
21.
AkaikeA., KanekoS., TamuraY., et al.Prostaglandin E2 protects cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 663:237–243, 1994.
22.
McCulloughL., WuL., HaugheyN., et al.Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24:257–268, 2004.
23.
LiuD., WuL., BreyerR., MattsonM.P., et al.Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann. Neurol. 57:758–761, 2005.
24.
AhmadA.S., ZhuangH., EcheverriaV., and DoréS.Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J. Neurotrauma. 23:1895–1903, 2006.
25.
CarrascoE., WernerP., and CasperD.Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci. Lett. 441:44–49, 2008.
26.
WoodwardD.F.EP2-Receptor Agonists as Agents for Lowering Intraocular Pressure. US Patent 5462968; 1995.
27.
WoodwardD.F.EP2 Receptor Agonists as Agents for Lowering Intraocular Pressure. US Patent 5698598; 1997.
28.
Andrade da CostaB.L., KangK.D., RittenhouseK.D., and OsborneN.N.The localization of PGE2 receptor subtypes in rat retinal cultures and the neuroprotective effect of the EP2 agonist butaprost. Neurochem. Int. 55:199–207, 2009.
29.
OsborneN.N., LiG.Y., JiD., et al.Expression of prostaglandin PGE2 receptors under conditions of aging and stress and the protective effect of the EP2 agonist butaprost on retinal ischemia. Invest. Ophthalmol. Vis. Sci. 50:3238–5248, 2009.
30.
NilssonS.F.E., DrecollE., Lütjen-DrecollE., et al.The prostaglandin EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 47:4042–4049, 2006.
31.
RichterM., KraussA.H.-P., WoodwardD.F., and Lütjen-DrecollE.Morphological changes in the anterior eye segment following long term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci. 44:4419–4426, 2003.
32.
WangJ.W., WoodwardD.F., and StamerW.D.Differential effects of prostaglandin E2-sensitve receptors on contractility of human ocular cells that regulate conventional outflow. Invest. Ophthalmol. Vis. Sci. 54:4782–4790, 2013.
33.
LiangY., LiC., GuzmanV.M., et al.Comparison of PGF2α, Bimatoprost (prostamide) and Butaprost (EP2 agonist) on Cyr 61 and CTGF gene expression. J. Biol. Chem. 278:27267–27277, 2003.
34.
WoodwardD.F., WangJ.W., ColemanR.A., et al.A highly effective and ultra-long acting anti-glaucoma drug with a new periorbital delivery method. J. Ocul. Pharmacol. Ther. 35:265–277, 2019.
35.
WoodwardD.F., GuzmanV.M., LiC., et al.Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br. J. Pharmacol. 154:1079–1093, 2008.
36.
MoriuchiH., KodaN., Okuda-AshitakaE., et al.Molecular characterization of a novel type of prostamide/prostaglandin F Synthase, belonging to the thioredoxin-like Superfamily. J. Biol. Chem. 283:792–801, 2008.
37.
GattaL., PiscitelliF., GiordanoC., et al.Discovery of prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS One. 7:e31111, 2012.
38.
UrquhartP., WangJ.W., WoodwardD.F., and NicolaouA.Identification of prostamides, fatty acyl ethanolamines and their biosynthetic precursors in rabbit cornea. J. Lipid Res. 56:1419–1433, 2015.
39.
MorrowJ.D., MintonT.A., MukundanC.R., et al.Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J. Biol. Chem., 269:4317–4326, 1994.
40.
WilsonS.J., RocheA.M., KostetskaiaE., and SmythE.M.Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J. Biol. Chem. 79:53036–53047, 2004.
41.
LawrenceR.A., and JonesR.L.Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. Br. J. Pharmacol. 105:817–824, 1992.
42.
NialsA.T., VardeyC.J., DenyerL.H., et al.AH 13205, a selective prostanoid EP2-receptor agonist. Cardiovasc. Drug Rev. 11:165–179, 1993.
43.
WoodwardD.F., ProtzmanC.E., KraussA.H.-P., and WilliamsL.S.Identification of 19 (R)-OH prostaglandin E2 as a selective prostanoid EP2-receptor agonist. Prostaglandins. 46:371–383, 1993.
44.
WoodwardD.F., ChanM.F., BurkeJ.A., et al.Studies on the ocular hypotensive effects of prostaglandin F2α ester prodrugs and receptor selective prostaglandin analogs. J. Ocul. Pharmacol. 10:177–193, 1993.
45.
DondeY., and NguyenJ.H.Therapeutic Prostaglandin Receptor Agonist. US Patent 934273; 2016.
46.
BurkR.M., HoloboskiM., and PosnerM.Omega-Cycloalkyl 17-Heteroalyl Prostaglandin E2 Analogs as EP2-Receptor Agonists. US Patent 6376533; 2002.
47.
BurkR.M., HoloboskiM., and PosnerM.Ω-Cycloalkyl 17-Heteroalyl Prostaglandin E2 Analogs as EP2-Receptor Agonists. US Patent 6586462; 2003.
48.
BurkR.M., HoloboskiM., and PosnerM.Ω-Cycloalkyl 17-Heteroalyl Prostaglandin E2 Analogs as EP2-Receptor Agonists. US Patent 6710072; 2004.
49.
BurkR.M., HoloboskiM., and PosnerM.Therapeutic Compounds. US Patent 7960378; 2011.
50.
OldD.W., GacT.S., and NgoV.X.Substituted Cyclopentanes or Cyclopentanones as Therapeutic Agents. US Patent 7323591; 2008.
51.
OldD.W., and NgoV.X.Therapeutic Substituted Chlorocyclopentanols. US Patent 7662850; 2010.
52.
DondeY., BurkR.M., and OldD.W.Therapeutic Compounds. US Patent 7799821; 2010.
53.
OldD.W., and NgoV.X.Therapeutic Compounds. US Patent 7981887; 2011.
54.
OldD.W., and NgoV.X.Therapeutic Compounds. US Patent 8252788; 2012.
55.
HoloboskiM., BurkR.M., DondeY., and OldD.W.Substituted Cyclopentanes Having Prostaglandin Activity. US Patent 8487091; 2013.
56.
OldD.W., and NgoV.X.Therapeutic Compounds. US Patent 8569349; 2013.
57.
DondeY., and NguyenJ.H.12-Aryl Prostaglandin Analogs. US Patent 7091231; 2006.
58.
DondeY., and NguyenJ.H.Substituted Arylcyclopentenes as Therapeutic Agents. US Patent 7713968; 2010.
59.
DondeY., NguyenJ.H., HoloboskiM., PosnerM., and BurkR.M.Therapeutic Compounds. US Patent 7964634; 2011.
60.
BurkR.M.Substituted Cyclopentanes Having Prostaglandin Activity. US Patent 8158676; 2012.
61.
DondeY., and NguyenJ.H.Therapeutic Compounds. US Patent 826359; 2012.
62.
DondeY., and NguyenJ.H.Therapeutic Compounds. US Patent 8278347; 2012.
63.
DondeY., and NguyenJ.H.Therapeutically Active Cyclopentanes. US Patent 8299068; 2012.
64.
BurkR.M.Substituted Cyclopentanes Having Prostaglandin Activity. US Patent 8455547; 2013.
65.
DondeY., and NguyenJ.H.Therapeutic Cyclopentane Derivatives. US Patent 8530471; 2013.
66.
DondeY., and NguyenJ.H.Substituted Cyclopentenes as Therapeutic Agents. US Patent 9000032; 2015.
67.
DondeY., and NguyenJ.H.Substituted Arylcyclopentenes as Therapeutic Agents. US Patent 9365485; 2016.
68.
DondeY.10, 10 dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure. US patent 6875787; 2005.
69.
OldD.W., DinhD.T., and BurkR.M.Therapeutic β-Lactams. US Patent 7674786; 2010.
70.
OldD.W., DinhD.T., and BurkR.M.Therapeutic β-Lactams. US Patent 7772392; 2010.
71.
OldD.W., and DinhD.T.Substituted Gamma Lactams as Therapeutic Agents. US Patent 7476747; 2009.
72.
OldD.W., and BurkR.M.Therapeutic Lactams. US Patent 7482475; 2009.
73.
OldD.W.Therapeutic Substituted Pyrrolidone Compounds. US Patent 7547685; 2009.
74.
OldD.W.Therapeutic Gamma Lactams as Therapeutic Agents. US Patent 7553860; 2009.
75.
OldD.W.Therapeutic Substituted Gamma Lactams. US Patent 7705001; 2010.
76.
OldD.W., and DinhD.T.Substituted Gamma Lactams as Therapeutic Agents. US Patent 7879854; 2011.
77.
OldD.W.Substituted Gamma Lactams as Therapeutic Agents. US Patent 7956055; 2011.
78.
OldD.W.Therapeutic Substituted Cyclic Lactams. US Patent 8198315; 2012.
79.
OldD.W., ImW.B., and NgoV.X.Therapeutic Substituted Lactams. US Patent 8362054; 2013.
80.
OldD.W., and BurkR.M.Therapeutic Lactams. US Patent Application 2015/0274658; 2015.
81.
OldD.W., DinhT.D., and BurkR.M.3-Oxa-8-Azaprostaglandin Analogs as Agents for Lowering Intraocular Pressure. US Patent 6734206; 2004.
82.
OldD.W., DinhD.T., and BurkR.M.8-Azaprostaglandin Analogs as Agents for Lowering Intraocular Pressure. US Patent 6573294; 2003.
83.
OldD.W., and DinhT.D.Piperidinyl Prostaglandin E Analogs. US Patent 6747037; 2004.
84.
OldD.W., and DinhD.T.Piperidinyl Prostaglandin E Analogs. US Patent 6977260; 2005.
85.
OldD.W., and DinhD.T.Piperidinyl Prostaglandin E Analogs. US Patent 7179820; 2007.
86.
OldD.W., and DinhD.T.5-Thiopiperidinyl Prostaglandin E Analogs. US Patent 7435746; 2008.
87.
OldD.W., and DinhD.T.Therapeutic Substituted Lactams. US Patent 8633310; 2014.
88.
OldD.W., DinhT.D., and BurkR.M.8-Azaprostaglandin Carbonate and Thiocarbonate Analogs as Therapeutic Agents. US Patent 7005442; 2004.
89.
OldD.W., and DinhD.T.Therapeutic Compounds. US Patent 7498447; 2009.
90.
OldD.W., and DinhD.T.Therapeutic Compounds. US Patent 7550448; 2009.
91.
OldD.W., and DinhD.T.Therapeutic N-Aryl or N-Heteroaryl Pyrazolidine and Pyrazolidinone Derivatives. US Patent 8093282; 2012.
92.
OldD.W., BurkR.M., and GacT.Therapeutic Amides. US Patent 8198318; 2012.
93.
OldD.W.Therapeutic Agents. US Patent 9051294; 2015.
94.
OldD.W.Therapeutic Agents for Ocular Hypertension. US Patent 9714238; 2017.
95.
TaniK., NaganawaA., IshidaA., et al.Development of a highly selective EP2-receptor agonist. Part 1: identification of 16-hydroxy-17, 17-trimethylene PGE2 derivatives. Bioorg. Med. Chem., 10:1093–1106, 2002.
96.
TaniK., NaganawaA., IshidaA., et al.Development of a highly selective EP2-receptor agonist. Part 2: identification of 16-hydroxy-17, 17-trimethylene 9-chloro-PGF derivatives. Bioorg. Med. Chem., 10:1107–1114, 2002.
97.
JonesR.L., WanA.N., AhmadW., et al.Nature of the slow relaxation of smooth muscle PGs. Leuk. Essent. Fatty Acids. 88:321–330, 2013.
98.
IwamuraR., TanakaM., OkanariE., et al.Identification of a selective, non-prostanoid EP2 receptor agonist for the treatment of glaucoma: omidenepag and its prodrug omidenepag isopropyl. J. Med. Chem. 61:6869–6891, 2018.
99.
ParalkarV.M., BoroveckiF., KeH.Z., et al.An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc. Nat. Acad. Sci. U. S. A. 100:6736–6740, 2003.
100.
SchacharR.A., RaberS., CourtneyR., and ZhangM.A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr. Eye Res. 36:809–817, 2011.
101.
WoodwardD.F., HawleyS.B., WilliamsL.S., et al.Studies on the ocular pharmacology of prostaglandin D2. Invest. Ophthalmol. Vis. Sci. 31:138–146, 1990.
102.
KostensisE., and UlvenT.Emerging roles of DP and CRTH2 receptors in allergic inflammation. Trends Mol. Med. 12:148–158, 2006.
103.
NatarajC., ThomasD.W., TilleyS.L., et al.Receptor for prostaglandin E2 that regulate cellular immune responses in the mouse. J. Clin. Invest. 108:1229–1235, 2001.
104.
WalkerW., and RotondoD.Prostaglandin E2 is a potent regulator of interleukin-12-and interleukin-18-induced natural killer cell interferon-γ synthesis. Immunology, 111:298–305, 2004.
105.
OkanoM., SugataY., FujiwaraT., et al.E prostanoid 2 (EP2)/EP4-mediated suppression of antigen specific human T-cell responses by prostaglandin E2. Immunology, 118:343–352, 2006.
106.
CheonH., RhoY.H., ChoiS.J.et al. Prostaglandin E2 augments IL-10 signaling and function. J. Immunol., 177:1092–1100, 2006.
107.
YanochkoG.M., AffolterT., EighmyJ.J., et al.Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. J. Ocul. Pharmacol. Ther. 30:429–439, 2014.
108.
SchacherR.A., RaberS., ThomasK.V., et al.Subclinical increased anterior stromal reflectivity with topical taprenepag isopropyl. Cornea, 32:306–312, 2013.
109.
BurkR.M., and ImW.B.Reduced Central Corneal Thickening by Use of Hydrophilic Ester Prodrugs of Beta-Chlorocyclopentanes. US Patent 9090595; 2015.
110.
BurkR.M., OldD.W., ImW.B., et al.Quaternary Ammonium Alkyl Esters as Stable Prodrugs. US Patent 9981938; 2018.
111.
BitoL.Z., and BaroodyR.A.The penetration of exogenous prostaglandin and arachidonic acid into, and their distribution within, the mammalian eye. Curr. Eye Res. 1:659–669, 1981–1982.
112.
BitoL.Z., and BaroodyR.A.The ocular pharmacokinetics of eicosanoids and their derivatives 1. Comparison of ocular eicosanoid penetration and distribution following topical application of PGF2alpha, PGF2alpha-1- methyl ester, and PGF2alpha-1-isopropyl ester. Exp. Eye Res., 44:217–226, 1987.
113.
WoodwardD.F., KraussA.H.-P., ChenJ., et al.Pharmacological characterization of a novel anti-glaucoma agent, Bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305:772–785, 2003.
114.
WoodwardD.F., WenthurS.L., RudebushT.L., et al.Prostanoid receptor effects on intraocular pressure, supported by ocular biodisposition experiments. J. Ocular Pharmacol. Ther. 32:606–622, 2016.
115.
HughesP.M., ShenJ., and RobinsonM.R.Prostamide-Containing Intraocular Implant. US 9289413; 2016.
116.
LewisR.A., ChristieW.C., DayD.G., et al.Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am. J. Ophthalmol. 175:137–147, 2017.
117.
Schlötzer-SchrehardtU., ZenkelM., and NüsingR.M.Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis. Sci. 43:1475–1487, 2002.
